Record #343283 - GSI Repository

FRATAXAV

Pre-clinical validation of a novel gene therapy for a rare disease in non-human primates: Integrative approach to the CMC scale-up process validation of a gene therapy product for Friedreich Ataxia

Grant period	2023-07-01 - 2024-06-30
Funding body	European Union
Call number	HORIZON-EIE-2022-SCALEUP-02
Grant number	101114192
Identifier	G:(EU-Grant)101114192

Note: Founded in 2018, Biointaxis is an academic spin-off company established by a team of researchers lead by a woman Scientist from the Research Institute Germans Trias i Pujol (IGTP) benefiting from extensive know-how in the identification of genes, biomarkers and translational mechanisms underlying neurodegenerative disorders. Our leading candidate, BTX-101, is currently the best-in-class product for the treatment of Friedreich’s Ataxia (FRDA), a rare devastating inherited, progressive, neurodegenerative disease typically affecting teenagers and young adults for whom there are no treatments. Our product proves treatment efficacy being able to re-establish the neurological and cardiac functions in two FRDA mice models. The product is patented (WO2019076973A1) becoming the first preclinical product ever to show life-long disease modifying activity both for neurological and cardiac symptoms in FRDA. Biointaxis has a unique know-how, based on years of fundamental research which has resulted in strong collaborations from important research centers including the Research Institute Germans Trias i Pujol (IGTP) affiliated to the Universitat Autònoma de Barcelona, top University in Spain; reference public Hospitals (University Hospital Germans Trias i Pujol in Badalona, The Virgen del Rocío University Hospital in Seville, Valdecilla University Hospital in Cantabria); public administration (Biocat - la Fundació BioRegió de Catalunya) and foundations (La Caixa, Federación de Ataxias de España, EuroAtaxia, STOP_Friedreich Ataxia), etc. BTX-101 has already been capable of attracting investment to Biointaxis with a €1M seed round in 2022. After sound pre-clinical and clinical validation completed in the next three years, BTX-101 will become also capable of attracting more interest from pharma customers for further validation and commercialization. Ultimately, Biointaxis aims to change the paradigm in Friedreich's ataxia and to defeat rare diseases to restore patient's health.

Recent Publications

There are no publications

Record created 2023-08-27, last modified 2023-08-27

Similar records

Add to personal basket
Export as Author List with IDs BibTeX (UTF-8), EndNote XML, EndNote Text, RIS, MARC, Print MARC, MARCXML, DC,
Request correction
Submit fulltext

GSI Homepage \| GSI Library \| English Deutsch \| guest :: login GSI Repository
Search	Submit	Personalize Your alerts Your baskets Your searches	Help